|
| Status |
Public on Jul 14, 2015 |
| Title |
02C patient |
| Sample type |
genomic |
| |
|
| Source name |
SCLC patient tumor
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: SCLC patient tumor
|
| Treatment protocol |
No treatment
|
| Growth protocol |
cell lines: RPMI with 10%FBS
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
All the procedure of bisulfite conversion, amplification, labeling and hybridization was performed following the protocol provided by Illumina
|
| Label |
Cy5 and Cy3
|
| Label protocol |
standard Illumina protocol
|
| |
|
| Hybridization protocol |
standard Illumina protocol
|
| Scan protocol |
standard Illumina protocol
|
| Data processing |
Data was processed and normalized using GenomeStudio V2011.1
|
| |
|
| Submission date |
Feb 25, 2015 |
| Last update date |
Jul 14, 2015 |
| Contact name |
David Soong |
| Organization name |
GlaxoSmithKline
|
| Street address |
1250 S Collegeville Rd
|
| City |
Collegeville |
| State/province |
PA |
| ZIP/Postal code |
19426 |
| Country |
USA |
| |
|
| Platform ID |
GPL13534 |
| Series (2) |
| GSE66295 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC (BeadChip) |
| GSE66298 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC |
|
